Table 3.
Covariates | Hazard ratio | 95% confidence interval | Log-rank test (∗ P < 0.05) |
---|---|---|---|
Angle-closure NVG group | 3.059 | 1.898–4.916 | 0.0002∗ |
Causative disease, PDR | 0.759 | 0.391–0.930 | 0.0002∗ |
Treatments, LEC | 0.412 | 0.251–0.667 | 0.0809 |
Causative disease, RVO | — | — | 0.0123∗ |
Causative disease, OIS | — | — | 0.0384∗ |
Previous treatments, PRP | — | — | 0.1667 |
Previous treatments, PPV | — | — | 0.2717 |
Pre-existing complications, hyphema | — | — | 0.3930 |
Pre-existing complications, VH | — | — | 0.8108 |
Treatments, anti-VEGF therapy | — | — | 0.3128 |
Treatments, additional PRP | — | — | 0.3642 |
Treatments, PPV | — | — | 0.9287 |
NVG, neovascular glaucoma; PDR, proliferative diabetic retinopathy; LEC, trabeculectomy with mitomycin C; RVO, retinal vein occlusion; OIS, ocular ischemic syndrome; PRP, panretinal laser photocoagulation; PPV, pars plana vitrectomy; VH, vitreous hemorrhage.